ITTIGEN and BERN, Switzerland, November 11, 2010 /PRNewswire/ -- Pevion
Biotech AG today announced positive preliminary results from a Phase I study
of PEV7, the first vaccine against recurrent vulvovaginal candidiasis (RVVC).
Also known as chronic recurrent thrush, RVVC is a highly debilitating